Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMC435350 (Simeprevir) in Genotype 1 Hepatitis C
NCT00561353Phase 2Completed
- Sponsor
- Tibotec
- Start
- Jan 2008
- Primary completion
- Dec 2008
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of simeprevir in hepatitis C (HCV) (10 arms), sponsored by Tibotec. Primary endpoint: Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 4 weeks. Started Jan 2008; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00561353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00561353.